PMC3398337_01
Abdominal MRI scans of patient 1 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
1752-1947-6-2-1.jpg
PMC3398337_01_1752-1947-6-2-1.jpg
F1
The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4).
Abdominal MRI scans of patient 2 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
1752-1947-6-2-2.jpg
PMC3398337_01_1752-1947-6-2-2.jpg
F2
The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4). Body fat thickness also increased in the flanks and back areas (only in patient 2; Figure 2) and the posterior surface of the thighs in both patients (Figures 3 and 4).
MRI scans of the thighs of patient 1 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
1752-1947-6-2-3.jpg
PMC3398337_01_1752-1947-6-2-3.jpg
F3
The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4). Body fat thickness also increased in the flanks and back areas (only in patient 2; Figure 2) and the posterior surface of the thighs in both patients (Figures 3 and 4).
MRI scans of the thighs of patient 2 when injecting pegvisomant (10 mg/day) subcutaneously in her abdomen (Phase 1) and thighs (Phase 2).
1752-1947-6-2-4.jpg
PMC3398337_01_1752-1947-6-2-4.jpg
F4
The MRI images and evaluation of fat mass content with DXA (Table 1) confirmed a reduction in abdominal subcutaneous fat thickness in patient 1 (Figure 1) and patient 2 (Figure 2), together with a concomitant increase in the subcutaneous fat at the anterior surface of both thighs in patient 1 (Figure 3) and patient 2 (Figure 4). Body fat thickness also increased in the flanks and back areas (only in patient 2; Figure 2) and the posterior surface of the thighs in both patients (Figures 3 and 4).